Format

Send to

Choose Destination
See comment in PubMed Commons below
Thrombosis. 2012;2012:867121. doi: 10.1155/2012/867121. Epub 2012 May 7.

Dabigatran for stroke prevention in nonvalvular atrial fibrillation: answers to challenging "real-world" questions.

Author information

  • 1Servi├žo de Cardiologia, Hospital de Santa Cruz, Avenida Prof. Reinaldo dos Santos, 2790-134 Carnaxide, Portugal.

Abstract

Dabigatran etexilate is a novel, oral, reversible, direct thrombin inhibitor that constitutes a major breakthrough for stroke prevention in patients with nonvalvular atrial fibrillation (AF). Dabigatran was the first new oral anticoagulant approved in Europe and became available in Portugal, for stroke prevention in nonvalvular AF, earlier than in most European countries. This paper is the joint effort of a panel of experts from different specialties and provides information on the use of dabigatran, in anticipation of the challenges that will come with increased usage.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00359424 NCT01468155.

PMID:
22645678
PMCID:
PMC3356980
DOI:
10.1155/2012/867121
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center